{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:33:13Z","timestamp":1784586793319,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study investigated the presence of designer benzodiazepines in 35 urine specimens obtained from emergency department patients undergoing urine drug screening. All specimens showed apparent false-positive benzodiazepine screening results (i.e., confirmatory testing using a 19-component liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS-MS) panel showed no prescribed benzodiazepines at detectable levels). The primary aims were to identify the possible presence of designer benzodiazepines, characterize the reactivity of commercially available screening immunoassays with designer benzodiazepines and evaluate the risk of inappropriately ruling out designer benzodiazepine use when utilizing common urine drug screening and confirmatory tests. Specimens were obtained from emergency departments of a single US Health system. Following clinically ordered drug screening using Abbott ARCHITECT c assays and laboratory-developed LC\u2013MS-MS confirmatory testing, additional characterization was performed for investigative purposes. Specifically, urine specimens were screened using two additional assays (Roche cobas c502 and Siemens Dimension Vista) and LC\u2013quadrupole time-of-flight mass spectrometry (LC\u2013QTOF-MS) to identify presumptively positive species, including benzodiazepines and non-benzodiazepines. Finally, targeted, qualitative LC\u2013MS-MS was performed to confirm the presence of 12 designer benzodiazepines. Following benzodiazepine detection using the Abbott ARCHITECT, benzodiazepines were subsequently detected in 28\/35 and 35\/35 urine specimens using Siemens and Roche assays, respectively. LC\u2013QTOF-MS showed the presumptive presence of at least one non-Food and Drug Administration (FDA)-approved benzodiazepine in 30\/35 specimens: flubromazolam (12\/35), flualprazolam (11\/35), flubromazepam (2\/35), clonazolam (4\/35), etizolam (9\/35), metizolam (5\/35), nitrazepam (1\/35) and pyrazolam (1\/35). Two or three designer benzodiazepines were detected concurrently in 13\/35 specimens. Qualitative LC\u2013MS-MS confirmed the presence of at least one designer benzodiazepine or metabolite in 23\/35 specimens, with three specimens unavailable for confirmatory testing. Urine benzodiazepine screening assays from three manufacturers were cross-reactive with multiple non-US FDA-approved benzodiazepines. Clinical and forensic toxicology laboratories using traditionally designed LC\u2013MS-MS panels may fail to confirm the presence of non-US FDA-approved benzodiazepines detected by screening assays, risking inappropriate interpretation of screening results as false positives.<\/jats:p>","DOI":"10.1093\/jat\/bkab108","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T03:15:30Z","timestamp":1632453330000},"page":"712-718","source":"Crossref","is-referenced-by-count":17,"title":["Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC\u2013QTOF-MS and LC\u2013MS-MS"],"prefix":"10.1093","volume":"46","author":[{"given":"Andrii","family":"Puzyrenko","sequence":"first","affiliation":[{"name":"Department of Pathology, Medical College of Wisconsin , 8701 W Watertown Plank Road, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Beaumont Health System, Beaumont Hospital\u2014Royal Oak , 3601 W 13 Mile Road, Royal Oak, MI 48073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Schneider","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics, Research & Development\u2014Scientific Affairs , 100 Abbott Park, Abbott Park, IL 60014, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Wallace","sequence":"additional","affiliation":[{"name":"Milwaukee County Medical Examiner\u2019s Office , 933 West Highland Avenue, Milwaukee, WI 53233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Milwaukee County Medical Examiner\u2019s Office , 933 West Highland Avenue, Milwaukee, WI 53233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Brandt","sequence":"additional","affiliation":[{"name":"ProHealth Waukesha Memorial Hospital , 725 American Avenue, Waukesha, WI 53188, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-0041","authenticated-orcid":false,"given":"Ian L","family":"Gunsolus","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical College of Wisconsin , 8701 W Watertown Plank Road, Milwaukee, WI 53226, USA"},{"name":"Department of Pathology and Laboratory Medicine, Health Partners , 8170, 33rd Avenue S, Minneapolis, MN 55425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"2022081310465469100_R1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Network Open"},{"key":"2022081310465469100_R2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881113503509","article-title":"Benzodiazepines: risks and benefits. A reconsideration","volume":"27","author":"Baldwin","year":"2013","journal-title":"Journal of Psychopharmacology"},{"key":"2022081310465469100_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15563650.2016.1217003","article-title":"New psychoactive substances (NPS)\u2014the Hydra monster of recreational drugs","volume":"55","author":"Helander","year":"2017","journal-title":"Clinical Toxicology"},{"key":"2022081310465469100_R4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jat\/bkaa043","article-title":"Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases","volume":"44","author":"Heide","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2022081310465469100_R5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/dta.2211","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: a review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Testing and Analysis"},{"key":"2022081310465469100_R6","volume-title":"European Drug Report 2020: Trends and Developments","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2020"},{"key":"2022081310465469100_R7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2018_160","volume-title":"New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology","author":"Evans-Brown","year":"2018"},{"key":"2022081310465469100_R8","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"2022081310465469100_R9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cpdd.667","article-title":"Designer benzodiazepines: a review of published data and public health significance","volume":"8","author":"Greenblatt","year":"2019","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"2022081310465469100_R10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.aca.2016.04.046","article-title":"Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices\u2014where do we stand today?","volume":"927","author":"Meyer","year":"2016","journal-title":"Analytica Chimica Acta"},{"key":"2022081310465469100_R11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clinms.2018.08.004","article-title":"Urine analysis of 28 designer benzodiazepines by liquid chromatography\u2013high-resolution mass spectrometry","volume":"10","author":"Pettersson Bergstrand","year":"2018","journal-title":"Clinical Mass Spectrometry"},{"key":"2022081310465469100_R12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays: immunoassay screening of designer benzodiazepines","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Testing and Analysis"},{"key":"2022081310465469100_R13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jat\/bky092","article-title":"A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines","volume":"43","author":"van Wijk","year":"2019","journal-title":"Journal of Analytical Toxicology"},{"key":"2022081310465469100_R14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/dta.1628","article-title":"Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics","volume":"6","author":"Moosmann","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"2022081310465469100_R15","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6834a2","article-title":"Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine\u201425 states, July\u2013December 2017 to January\u2013June 2018","volume":"68","author":"Gladden","year":"2019","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"key":"2022081310465469100_R16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jat\/bkaa059","article-title":"Quantification of 54 benzodiazepines and Z-drugs, including 20 designer ones, in plasma","volume":"45","author":"Degreef","year":"2021","journal-title":"Journal of Analytical Toxicology"},{"key":"2022081310465469100_R17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchromb.2016.08.047","article-title":"Development and application of a multi-component LC\u2013MS\/MS method for determination of designer benzodiazepines in urine","volume":"1035","author":"Pettersson Bergstrand","year":"2016","journal-title":"Journal of Chromatography B"},{"key":"2022081310465469100_R18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jat\/bkv122","article-title":"ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using Immunalysis \u00ae benzodiazepine kit","volume":"40","author":"O\u2019Connor","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2022081310465469100_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-016-0338-5","article-title":"Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam","volume":"35","author":"Katselou","year":"2017","journal-title":"Forensic Toxicology"},{"key":"2022081310465469100_R20","first-page":"217","article-title":"The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum","volume":"34","author":"Andersson","year":"2017","journal-title":"Nordisk Alkohol- & Narkotikatidskrift: NAT"},{"key":"2022081310465469100_R21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","article-title":"Flubromazolam\u2014a new life-threatening designer benzodiazepine","volume":"54","author":"\u0141ukasik-G\u0142\u0119bocka","year":"2016","journal-title":"Clinical Toxicology"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkab108\/40494067\/bkab108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/7\/712\/45413881\/bkab108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/7\/712\/45413881\/bkab108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:47:22Z","timestamp":1660387642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/46\/7\/712\/6374717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,9,24]]},"published-print":{"date-parts":[[2022,8,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkab108","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,9,24]]}}}